EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Determination of Δ9-tetrahydrocannabinol, 11-nor-carboxy-Δ9-tetrahydrocannabinol and cannabidiol in human plasma and urine after a commercial cannabidiol oil product intake

Ioannis Papoutsis iD, Vasiliki Hatzidouka, Stamatina-Panagoula Ntoupa, Apostolis Angelis, Artemisia Dona, Emmanouil Sakelliadis, Chara Spiliopoulou

Forensic Toxicology · 2024

DOI: 10.1007/s11419-024-00686-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Forensic Toxicology, 2024. Verfasst von Ioannis Papoutsis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Medicine and Toxicology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ipapoutsis@med.uoa.gr. Hauptthemen laut MEDLINE: Cannabidiol, Gas Chromatography-Mass Spectrometry, Dronabinol, Limit of Detection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Athens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cannabidiol (CBD) products are widely used for pain relief, sleep improvement, management of seizures etc. Although the concentrations of Δ 9 -tetrahydrocannabinol (Δ 9 -THC) in these products are low (≤0.3% w/w), it is important to investigate if its presence and/or that of its metabolite 11-nor-carboxy-Δ 9 -THC, is traceable in plasma and urine samples of individuals who take CBD oil products.

Methods

A sensitive GC/MS method for the determination of Δ 9 -THC, 11-nor-carboxy-Δ 9 -THC and CBD in plasma and urine samples was developed and validated. The sample preparation procedure included protein precipitation for plasma samples and hydrolysis for urine samples, solid-phase extraction and finally derivatization with N ,O-bis(trimethylsilyl)trifluoroacetamide) with 1% trimethylchlorosilane.

Results

For all analytes, the LOD and LOQ were 0.06 and 0.20 ng/mL, respectively. The calibration curves were linear ( R 2 ≥ 0.992), and absolute recoveries were ≥91.7%. Accuracy and precision were within the accepted range. From the analysis of biologic samples of 10 human participants who were taking CBD oil, it was realized that Δ 9 -THC was not detected in urine, while 11-nor-carboxy-Δ 9 -THC (0.69–23.06 ng/mL) and CBD (0.29–96.78 ng/mL) were found in all urine samples. Regarding plasma samples, Δ 9 -THC (0.21–0.62 ng/mL) was detected in 10, 11-nor-carboxy-Δ 9 -THC (0.20–2.44 ng/mL) in 35, while CBD (0.20–1.58 ng/mL) in 25 out of 38 samples, respectively.

Conclusion

The results showed that Δ 9 -THC is likely to be found in plasma although at low concentrations. In addition, the detection of 11-nor-carboxy-Δ 9 -THC in both urine and plasma samples raises questions and concerns for the proper interpretation of toxicological results, especially considering Greece’s zero tolerance law applied in DUID and workplace cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolGas Chromatography-Mass SpectrometryDronabinolLimit of DetectionHumansSolid Phase ExtractionMaleAdult

Stichwörter der Autor:innen

11-nor-carboxy-Δ9-tetrahydrocannabinolCBD productsForensic investigationPlasmaUrineΔ9-tetrahydrocannabinol

Substanzen

CannabidiolDronabinol11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid

Autor:innen und Institutionen

  • Department of Forensic Medicine and Toxicology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ipapoutsis@med.uoa.gr.
  • Department of Forensic Medicine and Toxicology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Division of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Ioannis Papoutsis

Förderung

  • University of Athens

Zitieren

APA

Papoutsis, I., Hatzidouka, V., Ntoupa, S. P., Angelis, A., Dona, A., Sakelliadis, E., & Spiliopoulou, C. (2024). Determination of Δ9-tetrahydrocannabinol, 11-nor-carboxy-Δ9-tetrahydrocannabinol and cannabidiol in human plasma and urine after a commercial cannabidiol oil product intake. Forensic Toxicology. https://doi.org/10.1007/s11419-024-00686-0

Vancouver

Papoutsis I, Hatzidouka V, Ntoupa SP, Angelis A, Dona A, Sakelliadis E, et al. Determination of Δ9-tetrahydrocannabinol, 11-nor-carboxy-Δ9-tetrahydrocannabinol and cannabidiol in human plasma and urine after a commercial cannabidiol oil product intake. Forensic Toxicology. 2024. doi:10.1007/s11419-024-00686-0

BibTeX
@article{Papoutsis2024,
  author = {Papoutsis, Ioannis and Hatzidouka, Vasiliki and Ntoupa, Stamatina-Panagoula and Angelis, Apostolis and Dona, Artemisia and Sakelliadis, Emmanouil and Spiliopoulou, Chara},
  title = {Determination of Δ9-tetrahydrocannabinol, 11-nor-carboxy-Δ9-tetrahydrocannabinol and cannabidiol in human plasma and urine after a commercial cannabidiol oil product intake},
  journal = {Forensic Toxicology},
  year = {2024},
  doi = {10.1007/s11419-024-00686-0}
}
Kostenlos starten →